Abstract | BACKGROUND: PROCEDURE: Utilizing a panel of genomically annotated neuroblastoma cell line models, we investigated the in vitro effects of combined BET/ MEK inhibition on cell proliferation and apoptosis. Furthermore, we evaluated the effects of combined inhibition in neuroblastoma xenograft models. RESULTS: Combined BET and MEK inhibition demonstrated synergistic effects on the growth and survival of a large panel of neuroblastoma cell lines through augmentation of apoptosis. A combination therapy slowed tumor growth in a non-MYCN-amplified, NRAS-mutated neuroblastoma xenograft model, but had no efficacy in an MYCN-amplified model harboring a loss-of-function mutation in NF1. CONCLUSIONS: Combinatorial BET and MEK inhibition was synergistic in the vast majority of neuroblastoma cell lines in the in vitro setting but showed limited antitumor activity in vivo. Collectively, these data do not support clinical development of this combination in high-risk neuroblastoma.
|
Authors | Jason R Healy, Lori S Hart, Alexander L Shazad, Maria E Gagliardi, Matthew Tsang, Jimmy Elias, Jacob Ruden, Alvin Farrel, Jo Lynne Rokita, Yimei Li, Anastasia Wyce, Olena Barbash, Vandana Batra, Minu Samanta, John M Maris, Robert W Schnepp |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 67
Issue 6
Pg. e28267
(06 2020)
ISSN: 1545-5017 [Electronic] United States |
PMID | 32307821
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 Wiley Periodicals, Inc. |
Chemical References |
- Antineoplastic Agents
- Proteins
- Pyridones
- Pyrimidinones
- bromodomain and extra-terminal domain protein, human
- Benzodiazepines
- trametinib
- molibresib
- MAP Kinase Kinase 1
- MAP2K1 protein, human
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
- Benzodiazepines
(pharmacology)
- Cell Proliferation
- Female
- Humans
- MAP Kinase Kinase 1
(antagonists & inhibitors)
- Mice
- Mice, SCID
- Neuroblastoma
(drug therapy, metabolism, pathology)
- Proteins
(antagonists & inhibitors)
- Pyridones
(pharmacology)
- Pyrimidinones
(pharmacology)
- Tumor Cells, Cultured
- Xenograft Model Antitumor Assays
|